HDLIPIDS2011

Role of sphingolipids in white matter dysfunction in Huntington's disease

 Coordinatore INSTITUTO NEUROLOGICO MEDITERRANEO- NEUROMED SRL 

 Organization address address: VIA ATINENSE 18
city: POZZILLI IS
postcode: 86077

contact info
Titolo: Dr.
Nome: Ferdinando
Cognome: Squitieri
Email: send email
Telefono: +39 0865 915248
Fax: +39 0865 927575

 Nazionalità Coordinatore Italy [IT]
 Totale costo 249˙911 €
 EC contributo 249˙911 €
 Programma FP7-PEOPLE
Specific programme "People" implementing the Seventh Framework Programme of the European Community for research, technological development and demonstration activities (2007 to 2013)
 Code Call FP7-PEOPLE-2011-IIF
 Funding Scheme MC-IIF
 Anno di inizio 2013
 Periodo (anno-mese-giorno) 2013-06-10   -   2015-06-09

 Partecipanti

# participant  country  role  EC contrib. [€] 
1    INSTITUTO NEUROLOGICO MEDITERRANEO- NEUROMED SRL

 Organization address address: VIA ATINENSE 18
city: POZZILLI IS
postcode: 86077

contact info
Titolo: Dr.
Nome: Ferdinando
Cognome: Squitieri
Email: send email
Telefono: +39 0865 915248
Fax: +39 0865 927575

IT (POZZILLI IS) coordinator 249˙911.60

Mappa


 Word cloud

Esplora la "nuvola delle parole (Word Cloud) per avere un'idea di massima del progetto.

levels    gm    dysfunctions    myelin    decreased    ganglioside    models    cells    disease    white    applicant    metabolism    pathogenesis    hd    dysregulation    suggesting    symptomatic    gangliosides    htt   

 Obiettivo del progetto (Objective)

'Huntington’s disease (HD) is a neurodegenerative disorder caused by expansion of a CAG repeat, within the gene encoding huntingtin (Htt) and characterized by the progressive neurodegeneration and associated motor, cognitive and behavioral disturbances. Mutant Htt exerts adverse effects in neurons and non-neuronal cells. Animal studies describe white matter segmentation and myelin breakdown in HD. These evidences recapitulate the brain white matter volume loss described in pre-symptomatic and symptomatic subjects suggesting that white matter dysfunctions may represent a critical determinant in HD pathogenesis and may be identified as an early event of the disease. Recently, the applicant indentified a new dysfunctional pathway in HD, the dysregulation of ganglioside metabolism. High levels of gangliosides, in particular GM1, have been found to localize also in the myelin sheaths of oligodendrocytes where they play a crucial role in the maintenance of myelin integrity and in the regulation of axon–glia interactions. The applicant demonstrated that levels of GM1 are decreased in HD models and in fibroblasts from HD patients, contributing to heighten HD cells susceptibility to apoptosis. Importantly, administration of GM1 restored ganglioside levels and induced protective effects in HD models suggesting a therapeutic potential of GM1 in CNS. Our hypothesis is that decreased levels of GM1 may also affect white matter homeostasis. Interestingly, no studies correlating the dysregulation in gangliosides metabolism with white matter defects in HD have been conducted, so far. Thus, the main goal of this study is to look for white matter abnormalities and to determine the relationship with the degree of ganglioside dysfunctions and the severity of clinical status in HD. This will represent a new and interesting line of investigation in the field of HD and will provide more clear and deep understanding of the molecular mechanisms underlying the pathogenesis of the disease.'

Altri progetti dello stesso programma (FP7-PEOPLE)

RENAISSANCE (2012)

TRAINING NETWORK IN INNOVATIVE POLYELECTROLYTES FOR ENERGY AND ENVIRONMENT

Read More  

TREUEVALUE (2011)

TRans-national EUropean Ecosystem VALUEs of grasslands

Read More  

MATES (2014)

Understanding and predicting multispecies assemblages and interactions in space and time

Read More